Accumulation of Aβ peptide in the brains of individuals with Alzheimer disease leads to an inflammatory response. New data suggest that this response may not always be harmful.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–766 (2001).
Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383–421 (2000).
McGeer, P.L., Schulzer, M. & McGeer, E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies [see comments]. Neurology 47, 425–432 (1996).
Wyss-Coray, T. et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl Acad. Sci. USA 99, 10837–10842 (2002).
Davoust, N. et al. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163, 6551–6556 (1999).
Bao, L. et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J. Immunol. 168, 3601–3607 (2002).
Wyss-Coray, T. et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612–618 (2001).
Jantzen, P.T. et al. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide–releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 2246–2254 (2002).
DiCarlo, G., Wilcock, D., Henderson, D., Gordon, M. & Morgan, D. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice. Neurobiol. Aging 22, 1007–1012 (2001).
Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000).
Holtzman, D.M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 2892–2897 (2000).
Potter, H., Wefes, I.M. & Nilsson, L.N. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol. Aging 22, 923–930 (2001).
Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212–216 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Golde, T. Inflammation takes on Alzheimer disease. Nat Med 8, 936–938 (2002). https://doi.org/10.1038/nm0902-936
Issue Date:
DOI: https://doi.org/10.1038/nm0902-936
This article is cited by
-
The effects of two-stage carotid occlusion on spatial memory and pro-inflammatory markers in the hippocampus of rats
The Journal of Physiological Sciences (2017)
-
Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect
Drugs & Aging (2015)
-
Telomere Shortening and Alzheimer’s Disease
NeuroMolecular Medicine (2013)
-
Oxidative Stress and β-Amyloid Protein in Alzheimer’s Disease
NeuroMolecular Medicine (2011)